LONG-TERM MORBIDITY AND QUALITY OF LIFE IN CERVICAL CANCER SURVIVORS; A MULTICENTRE COMPARISSON BETWEEN SURGERY AND RADIOTHERAPY AS PRIMARY TREATMENT

Author(s):  
Marloes Derks
2014 ◽  
Vol 8 (3) ◽  
pp. 419-426 ◽  
Author(s):  
Howard P. Greenwald ◽  
Ruth McCorkle ◽  
Kathy Baumgartner ◽  
Carolyn Gotay ◽  
Anne Victoria Neale

2005 ◽  
Vol 97 (2) ◽  
pp. 310-317 ◽  
Author(s):  
Lari Wenzel ◽  
Israel DeAlba ◽  
Rana Habbal ◽  
Brenda Coffey Kluhsman ◽  
Diane Fairclough ◽  
...  

2005 ◽  
Vol 5 (3) ◽  
pp. 157-158
Author(s):  
Brigitte Miller

2013 ◽  
Vol 129 (1) ◽  
pp. 222-228 ◽  
Author(s):  
Gwenael Le Borgne ◽  
Mariette Mercier ◽  
Anne-Sophie Woronoff ◽  
Anne-Valérie Guizard ◽  
Edwige Abeilard ◽  
...  

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 317
Author(s):  
Mihai Stanca ◽  
Dan Mihai Căpîlna ◽  
Cristian Trâmbițaș ◽  
Mihai Emil Căpîlna

(1) Background: Cervical cancer patients have been found to have worse quality of life (QoL) scores due to cancer treatment, not only when compared to the general population, but also when compared to other gynecological cancer survivors. In Eastern European developing countries, the health care system often cannot afford the uppermost standardized treatment for these patients. In the absence of a comparable study in our country, the authors’ aim for this retrospective cross-sectional observational study was to evaluate the overall survival (OS) and the QoL o cervical cancer survivors; (2) Methods: 430 patients were analyzed. The first objective is to evaluate the OS rates of patients with cervical cancer stages IA2 to IIB undergoing radical hysterectomy (RH) +/− neoadjuvant or adjuvant radiotherapy +/− chemoradiotherapy treatment combinations. The second objective is to assess their QoL, using two standardized questionnaires issued by the European Organisation for Research and Treatment of Cancer (EORTC), namely QLQ-C30 and QLQ-CX24. (3) Results: The mean age of the participants was 51 years (22–76) and the average follow-up time was 65 months (2–128). At the time of the analysis, 308 out of 430 patients were alive, with a mean five-year OS of 72.4%. The multivariate Cox regression analysis identified stage IIB, parametrial invasion, and the lymph node metastases as independent prognostic risk factors negatively impacting the OS. Of the 308 patients still alive at the time of the analysis, 208 (68%) answered the QoL questionnaires. The QLQ-C30 shows a good long-term Global QoL of 64.6 (median), good functioning scores, and a decent symptom scale value. However, the EORTC QLQ-CX24 showed high values of cervical cancer-specific symptoms, namely: lymphedema, peripheral neuropathy, severe menopausal symptoms, and distorted body-image perception. The results also indicate a significant decline in the quality of sexual life with a low sexual enjoyment and decreased level of sexual activities. (4) Conclusion: Despite a good OS, in this setting of patients, cervical cancer survivors have a modest QoL and sexual function. Our study may provide a comparison for future randomized, controlled trials in Eastern European countries needing to confirm these results.


2005 ◽  
Vol 5 (3) ◽  
pp. 157-158
Author(s):  
Brigitte E. Miller

2017 ◽  
Vol 27 (2) ◽  
pp. 350-356 ◽  
Author(s):  
Marloes Derks ◽  
Luc R.C.W. van Lonkhuijzen ◽  
Rinske M. Bakker ◽  
Anne M. Stiggelbout ◽  
Cornelis D. de Kroon ◽  
...  

ObjectiveTo compare long-term morbidity and quality of life after primary surgery or primary radiotherapy for stage IB/II cervical cancer.MethodsA cross-sectional study was performed. Patients treated for stage IB/II cervical cancer between 2000 and 2010 were approached to participate. Primary treatment consisted of radical hysterectomy with pelvic lymphadenectomy (RHL), for selected cases followed by adjuvant (chemo-)radiotherapy, or primary (chemo)radiotherapy (PRT). European Organization for Research and Treatment of Cancer-C30 and European Organization for Research and Treatment of Cancer-CX24 questionnaires were administered. A multivariable analysis was performed to identify factors associated with morbidity/quality of life. In a subgroup analysis, we compared patients with RHL + adjuvant radiotherapy with those after PRT.ResultsThree hundred twenty-three cervical cancer survivors were included (263 RHL/60 PRT). In the PRT group, International Federation of Gynecology and Obstetrics stage was higher and women were older. In the RHL group, more women had a partner. Women treated with PRT reported lower physical (β, −6.01) and social functioning (β, −15.2), more financial problems (β, 10.9), diarrhea (β, 9.98), symptom experience (β, 6.13), sexual worry (β, 11.3), and worse sexual/vaginal functioning (β, 11.4). Women treated with RHL reported significantly more lymphedema (β, −16.1). No differences in global health were found. In the subgroup analysis, women after PRT (n = 60) reported poorer social functioning, less sexual enjoyment, and higher symptoms experience than women after RHL and adjuvant radiotherapy (n = 60). The latter reported more lymphedema.ConclusionsAlthough global health scores are not significantly different, women after PRT report more physical, social, and sexual symptoms. These results can be well used by physicians to inform their patients about treatment-related morbidity.


2015 ◽  
Vol 51 ◽  
pp. S540
Author(s):  
J. Khalil ◽  
H. Elkacemi ◽  
N. Sahli ◽  
F. El Omrani ◽  
T. Kebdani ◽  
...  

2008 ◽  
Vol 173 (10) ◽  
pp. 1035-1041 ◽  
Author(s):  
Carolyn C. Gotay ◽  
John H. Farley ◽  
Crissy Terawaki Kawamoto ◽  
Adela Mearig

Sign in / Sign up

Export Citation Format

Share Document